A performance evaluation of three drug-induced liver injury biomarkers in the rat: Alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase

Toxicological Sciences

Volumn 130, Issue 2, 2012, Pages 229-244

  Bailey, Wendy J ^a   Holder, Dan ^b   Patel, Hima ^a   Devlin, Pam ^a   Gonzalez, Raymond J ^a   Hamilton, Valerie ^a   Muniappa, Nagaraja ^a   Hamlin, Diane M ^c   Thomas, Craig E ^c   Sistare, Frank D ^a   Glaab, Warren E ^a  

^a Safety Assessment and Laboratory Animal Resources   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

4 hydroxyphenylpyruvate dioxygenase (HPD); Alpha glutathione S alkyltransferase (GSTA); Arginase 1 (ARG1); Biomarker; Hepatotoxicity; Rat

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; ALANINE AMINOTRANSFERASE; ARGINASE 1; GLUTATHIONE TRANSFERASE ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; DEGENERATION; FEMALE; HISTOPATHOLOGY; LIVER CELL DAMAGE; LIVER NECROSIS; LIVER TOXICITY; MALE; NONHUMAN; RAT; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ALANINE TRANSAMINASE; ANIMALS; ARGINASE; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUTATHIONE TRANSFERASE; ISOENZYMES; LINEAR MODELS; LIVER; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; ROC CURVE; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

EID: 84869400376     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs243     Document Type: Article

References (37)

1. Abei, M., Tanaka, N., Osuga, T., and Harada, S. (1989). Immunochemical properties and immunohistological localization of human liver glutathione S-transferase isozymes. Nihon Shokakibyo Gakkai Zasshi 86, 2728-2734.
2. Abraham, S. C., and Furth, E. E. (1995). Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 59, 740-746.
3. Aithal, P. G., and Day, C. P. (1999). The natural history of histologically proved drug induced liver disease. Gut 44, 731-735.
4. Amacher, D. E. (2002). A toxicologist's guide to biomarkers of hepatic response. Hum. Exp. Toxicol. 21, 253-262.
5. Awasthi, Y. C., Sharma, R., and Singhal, S. S. (1994). Human glutathione S-transferases. Int. J. Biochem. 26, 295-308.
6. Barksdale, A. R., Bernard, A. C., Maley, M. E., Gellin, G. L., Kearney, P. A., Boulanger, B. R., Tsuei, B. J., and Ochoa, J. B. (2004). Regulation of arginase expression by T-helper II cytokines and isoproterenol. Surgery 135, 527-535.
7. Bergmeyer, H. U., Hørder, M., and Rej, R. (1986). International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J. Clin. Chem. Clin. Biochem. 24, 481-495.
8. Campbell, J. A., Corrigall, A. V., Guy, A., and Kirsch, R. E. (1991). Immunohistologic localization of alpha, mu, and pi class glutathione S-transferases in human tissues. Cancer 67, 1608-1613.
9. Ennulat, D., Magid-Slav, M., Rehm, S., and Tatsuoka, K. S. (2010). Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat. Toxicol. Sci. 116, 397-412.
10. FDA-Guidance. (2007). Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests, pp. 1-39. U.S. Department of Health and Human Services Food and Drug Administration, Office of Serveillance and Biometrics, Washington DC.
11. Goodsaid, F. M., Amur, S., Aubrecht, J., Burczynski, M. E., Carl, K., Catalano, J., Charlab, R., Close, S., Cornu-Artis, C., Essioux, L., et al. (2010). Voluntary exploratory data submissions to the U.S. FDA and the EMA: Experience and impact. Nat. Rev. Drug Discov. 9, 435-445.
12. Harrell, F. E., Jr. (2001). Regression Modeling Strategies, Chapter 10. Springer Science, New York, NY.
13. Hummel, R., Nørgaard, P., Andreasen, P. H., Neve, S., Skjødt, K., Tornehave, D., and Kristiansen, K. (1992). Tetrahymena gene encodes a protein that is homologous with the liver-specific F-antigen and associated with membranes of the Golgi apparatus and transport vesicles. J. Mol. Biol. 228, 850-861.
14. Ikemoto, M., Ishida, A., Tsunekawa, S., Ozawa, K., Kasai, Y., Totani, M., and Ueda, K. (1993). Enzyme immunoassay of liver-type arginase and its potential clinical application. Clin. Chem. 39, 794-799.
15. Ikemoto, M., Tabata, M., Miyake, T., Kono, T., Mori, M., Totani, M., and Murachi, T. (1990). Expression of human liver arginase in Escherichia coli. Purification and properties of the product. Biochem. J. 270, 697-703.
16. Ikemoto, M., Tabata, M., Murachi, T., and Totani, M. (1989). Purification and properties of human erythrocyte arginase. Ann. Clin. Biochem. 26(Pt 6), 547-553.
17. Mattes, W. B., Walker, E. G., Abadie, E., Sistare, F. D., Vonderscher, J., Woodcock, J., and Woosley, R. L. (2010). Research at the interface of industry, academia and regulatory science. Nat. Biotechnol. 28, 432-433.
18. Miyanaka, K., Gotoh, T., Nagasaki, A., Takeya, M., Ozaki, M., Iwase, K., Takiguchi, M., Iyama, K. I., Tomita, K., and Mori, M. (1998). Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem. J. 30, 741-751.
19. Mulder, T. P., Court, D. A., and Peters, W. H. (1999). Variability of glutathione S-transferase alpha in human liver and plasma. Clin. Chem. 45, 355-359.
20. Nathwani, R. A., Kumar, S. R., Reynolds, T. B., and Kaplowitz, N. (2005a). Marked elevation in serum transaminases: An atypical presentation of choledocholithiasis. Am. J. Gastroenterol. 100, 295-298.
21. Nathwani, R. A., Pais, S., Reynolds, T. B., and Kaplowitz, N. (2005b). Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 41, 380-382.
22. Neve, S., Aarenstrup, L., Tornehave, D., Rahbek-Nielsen, H., Corydon, T. J., Roepstorff, P., and Kristiansen, K. (2003). Tissue distribution, intracellular localization and proteolytic processing of rat 4-hydroxyphenylpyruvate dioxygenase. Cell Biol. Int. 27, 611-624.
23. Ochoa, J. B., Bernard, A. C., O'Brien, W. E., Griffen, M. M., Maley, M. E., Rockich, A. K., Tsuei, B. J., Boulanger, B. R., Kearney, P. A., and Morris, S. M., Jr. (2001). Arginase I expression and activity in human mononuclear cells after injury. Ann. Surg. 233, 393-399.
24. Ozer, J., Ratner, M., Shaw, M., Bailey, W., and Schomaker, S. (2008). The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194-205.
25. Pencina, M. J., D'Agostino, R. B., Sr, D'Agostino, R. B., Jr, and Vasan, R. S. (2008). Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157-172; discussion 207.
26. Pratt, D. S., and Kaplan, M. M. (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 342, 1266-1271.
27. Prozialeck, W. C., Edwards, J. R., Vaidya, V. S., and Bonventre, J. V. (2009). Preclinical evaluation of novel urinary biomarkers of cadmium nephrotoxicity. Toxicol. Appl. Pharmacol. 238, 301-305.
28. Shaw, M. (2005). The use of histologically defined specific biomarkers in drug development with special reference to the glutathione S-transferases. Cancer Biomark. 1, 69-74.
29. Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005). ROCR: Visualizing classifier performance in R. Bioinformatics 21, 3940-3941.
30. Sistare, F. D., Dieterle, F., Troth, S., Holder, D. J., Gerhold, D., Andrews-Cleavenger, D., Baer, W., Betton, G., Bounous, D., Carl, K., et al. (2010). Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol. 28, 446-454.
31. Solter, P. F. (2005). Clinical pathology approaches to hepatic injury. Toxicol. Pathol. 33, 9-16.
32. Tietz, N. (1995). Clinical Guide to Laboratory Tests, 3rd ed. WB Saunders Co., Philadelphia, PA.
33. Travlos, G. S., Morris, R. W., Elwell, M. R., Duke, A., Rosenblum, S., and Thompson, M. B. (1996). Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. Toxicology 107, 17-29.
34. Wang, P. Y., Kaneko, T., Tsukada, H., Nakano, M., Nakajima, T., and Sato, A. (1997). Time courses of hepatic injuries induced by chloroform and by carbon tetrachloride: Comparison of biochemical and histopathological changes. Arch. Toxicol. 71, 638-645.
35. Warnock, D. G., and Peck, C. C. (2010). A roadmap for biomarker qualification. Nat. Biotechnol. 28, 444-445.
36. Watkins, P. B. (2005). Idiosyncratic liver injury: Challenges and approaches. Toxicol. Pathol. 33, 1-5.
37. Watkins, P. B., Kaplowitz, N., Slattery, J. T., Colonese, C. R., Colucci, S. V., Stewart, P. W., and Harris, S. C. (2006). Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial. JAMA 296, 87-93.